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Abstract 
Background and Purpose: Glucagon-like peptide-1 (GLP-1) is an incretin hormone that 
regulates insulin biosynthesis and secretion in a glucose-dependent manner, and has been 
reported to induce vasodilatation. Here, the aim was to examine the possible vasorelaxant 
effect of GLP-1 and the underlying mechanisms.  
Experimental Approach: Rat mesenteric arteries (diameter ≈ 200-400 µm) and human 
subcutaneous arteries were mounted in microvascular myographs for isometric tension 
recordings. The effect of GLP-1 on vascular responses was examined at normoglycemic 
conditions and at high glucose.  
Key Results: In rat mesenteric arteries and human subcutaneous arteries without branches, 
physiological concentrations (1-100 nM) of GLP-1(7-36) and liraglutide failed to cause 
relaxation, or affect contractions evoked by electrical field stimulation. In contrast to GLP-
1(7-36), liraglutide induced relaxations antagonized by the GLP-1 receptor antagonist, 
exendin-(9-39) in branched mesenteric arteries. In contrast to liraglutide, GLP-1 leftward 
shifted concentration relaxation curves for bradykinin in subcutaneous arteries from patients 
with peripheral arterial disesase, an effect insensitive to exendin-(9-39). In normoglycemic 
conditions neither GLP-1 nor liraglutide changed acetylcholine relaxation in rat mesenteric 
arteries. In arteries exposed to 40 mM glucose, GLP-1, in contrast to liraglutide, potentiated 
acetylcholine-induced relaxation by a mechanism that was not antagonized by exendin-(9-
39). GLP-1 decreased superoxide levels measured with dihydroethidium in rat mesenteric 
arteries exposed to 40 mM glucose.  
Conclusion and Implications: Our findings suggest that a GLP-1 receptor-dependent 
mechanism is involved in liraglutide relaxation in branched arteries in normoglycemic 
conditions, while GLP-1 inhibition of vascular superoxide levels contributes to GLP-1 
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receptor-independent potentiation of endothelium-dependent vasodilatation in 
hyperglycemia. 
Keywords: GLP-1, liraglutide, resistance vessels, high glucose, endothelium dependent 
relaxation, neuronal inhibition. 
Abbreviations:  
ACh, acetylcholine; AUC, area under the curve; DPP-4, dipeptidyl peptidase 4; GLP-1, 
glucagon-like peptide-1; GLP-1R, glucagon-like peptide-1 receptor; EFS, electrical field 
stimulation; PEG-SOD, polyethylene glycol superoxide dismutase. 
Bullet summary 
What is already known? 
 GLP-1 is an incretin hormone reported to induce vasodilatation and lower blood 
pressure  
What this study adds? 
 GLP-1 and the GLP-1 analogue induce vasodilatation by GLP-1R independent and 
dependent mechanisms 
Clinical significance? 
 Different GLP-1 analogue effects may help in optimizing prevention of 
cardiovascular complications in type-2 diabetes 
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Introduction 
Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone secreted in response to 
nutrient ingestion. GLP-1 has a blood glucose lowering effect by stimulating an increase in 
insulin biosynthesis and secretion and by inhibiting glucagon secretion in a glucose 
dependent manner. Moreover, GLP-1 inhibits gastric emptying, augments satiety, and 
promotes a weight loss (Holst, 2004;Davies et al., 2015). Growing evidence suggests that it 
may also play a role in the regulation of cardiovascular function (Drucker, 2016). The GLP-1 
analogue liraglutide is approved for the treatment of type 2 diabetes mellitus (T2D) and 
obesity (Ussher & Drucker, 2014;EMA, 2017) and has been found to reduce blood pressure 
and the risk of cardiovascular events (Fonseca et al., 2014;Gejl et al., 2015;Marso et al., 
2016;Starup-Linde et al., 2014). GLP-1 and liraglutide bind to the GLP-1 receptor (GLP-1R), 
a G-protein-coupled receptor (Ussher & Drucker, 2014; Alexander et al., 2017). In the 
cardiovascular system, the GLP-1R has been found to be expressed in smooth muscle cells, 
the sinoatrial node (Pyke et al., 2014), the myocardium and microvascular endothelium (Ban 
et al., 2008;Bhashyam et al., 2010). However, some papers have questioned data obtained 
using standard antisera to detect the GLP-1R (Pyke & Knudsen, 2013;Panjwani et al., 2012).  
   GLP-1R agonists have been found to induce vasodilatation, increase blood flow, and to 
improve vascular endothelial function (Drucker, 2016;Gejl et al., 2012), but the results of 
studies in isolated arteries are conflicting. Generally, it has been assumed that the 
vasodilatory actions of GLP-1 is GLP-1R-dependent, but some studies proposed vascular 
effects independent of the GLP-1R (Ban et al., 2008). It has also been questioned whether the 
cleaved metabolite, GLP-1(9-36), of native GLP-1(7-36) plays a role (Bayram et al., 
2014;Ban et al., 2008). Several pathways have been suggested to mediate the vascular effects 
of GLP-1R agonists. These includes direct effect on the smooth muscle cells, endothelium-
dependent release of nitric oxide (NO) (Nystrom et al., 2005), and pathways involving an 
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increase in cyclic GMP or cyclic AMP as well as protection against endothelial dysfunction 
(Ban et al., 2008;Green et al., 2008;Bayram et al., 2014;Koska et al., 2015;Salheen et al., 
2015). However, an indirect vasoconstricting effect of GLP-1 causing inhibition of 
relaxations induced by vascular endothelial growth factor (VEGF) has also been described in 
mesenteric arteries and was associated with a decrease in endothelial cell calcium (Egholm et 
al., 2016). Therefore, the effect on vascular tone of GLP-1 is unclear, and a possible effect of 
GLP-1 on the peripheral autonomic nervous system has not been examined despite the fact 
that several other gut-derived peptides regulate the release of noradrenaline in the vasculature 
(Gradin et al., 2006). Moreover, hyperglycemia generates reactive oxygen species suggested 
to impair endothelium dependent relaxation, and growing evidence reveals that GLP-1 
receptor stimulation may reduce ROS (Salheen et al., 2015;Steven et al., 2017), and hence 
improve endothelial function (Salheen et al., 2015).  
   In the present study, we aimed to examine the pre-junctional and post-junctional 
vasorelaxant effects of native GLP-1(7-36), liraglutide and GLP-1(9-36) in rat and human 
resistance vessels, to elucidate the signaling pathways involved in GLP-1-mediated 
regulation of vascular tone. We hypothesized that GLP-1R stimulation regulates vascular 
tone either by a direct impact on signaling pathways determining the contractile level of the 
smooth muscle cells, by an endothelium-dependent pathway, or through inhibition of 
noradrenaline release from nerves in the vascular wall during conditions with increased 
sympathetic nerve activity. Moreover, we aimed to investigate whether GLP-1 by inhibition 
of superoxide may improve acetylcholine relaxations in rat mesenteric arteries exposed to 
hyperglycemic conditions. 
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Materials and methods 
Tissue preparations 
All animal experiments were conducted in accordance with the Danish legislation of animal 
use for scientific procedures and approved by the Danish Experimental Animal Inspectorate 
(permission 2014-15-2934-01059) according to the ARRIVE guidelines (McGrath & Lilley, 
2015). Adult male Wistar rats (10-12 weeks old) of the Hannover strain (RGD Cat# 1566433, 
RRID:RGD_1566433) and weighing 300-350 g were obtained either at Taconic, Ry, 
Denmark or from Janvier Laboratories, France. The rats were housed in cages (Techniplast, 
800 cm
2
) filled with aspen woodchips (Tapvei, Datesand, Manchester, UK) and nesting 
material (Soft Paper Wool/LBS, UK) as bedding and under constant climatic conditions 
(20°C, 60 % humidity, 12-h:12-h light-dark cycle). The animals got food (Altromin 1324, 
Brogaarden ApS, DK) and water ad libitum.  
The animals were selected randomly and, wherever possible, observations were made without 
knowledge of the treatments administered. The rats were killed by a blow to the head 
followed by exsanguination. The mesenteric bed was removed, and it was immediately 
placed in cold physiological salt solution (4°C) of the following composition (mM): NaCl 
119, KCl 4.7, KH2PO4 1.18, MgSO4 1.17, NaHCO3 25, CaCl2 1.6, EDTA 0.026 and glucose 
5.5. The solution was gassed with 5% CO2 in air to maintain the pH at 7.4. Third order 
mesenteric arteries (internal diameter ≈ 200-300 µm) were dissected without branches 
(straight segments) or with at least one major branch (branched vessels).  
   Human arteries were obtained from the Department of Vascular Surgery, Aalborg 
University Hospital. Subcutaneous tissue samples were obtained from 23 patients undergoing 
vascular surgery, and they were placed in cold physiological salt solution immediately after 
extraction. Subcutaneous arteries with internal diameters ≈ 200-400 µm were dissected. The 
study was approved by the Regional Ethics Committee, Central Denmark (permission 
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number: 1-10-72-208-15), and conducted in accordance with the principles of Helsinki 
Declaration II for medical research. All participants gave informed consent prior to 
participation. To be included in the study, the patients had to be, 1) adult competent persons, 
2) Caucasians, 3) diagnosed with peripheral arterial disease or ischemic heart disease. Both 
diabetic and non-diabetic patients were included. The patients were excluded, if they were 
currently treated with GLP-1 analogues.   
Isometric tension recordings 
Arterial segments (approximately 2 mm long) were mounted on two wires (40 µm in 
diameter) in microvascular myographs (Danish Myotechnology, Aarhus, Denmark) for 
isometric tension recordings. The vessels equilibrated in oxygenated (5% CO2 in air) 
physiological salt solution (pH 7.4) heated to 37°C. To determine the lumen diameter that the 
artery would have had in vivo when relaxed and under a transmural pressure of 100 mmHg, 
the vessels were stretch following a standardized procedure. Arteries were set to 90% of this 
diameter, which is the optimal vessel circumference for maximal force development 
(Mulvany & Halpern, 1977). To test tissue viability, arterial segments were subjected to an 
isotonic physiological salt solution containing a high concentration of potassium (123 mM) or 
noradrenalin (1-10 µM) resulting in maximal contraction of the vessels. To test endothelial 
function, the vessels were contracted with phenylephrine or noradrenalin, and then stimulated 
with acetylcholine (10 µM) in rat arteries, and with bradykinin (30 nM) in human arteries. 
Only rat mesenteric arteries relaxing more than 75% to acetylcholine and human 
subcutaneous arteries relaxing more than 50 % to bradykinin were included in the study. 
   The possible direct effect of GLP-1 and analogues in rat and human resistance arteries was 
examined by adding increasing cumulative concentrations of GLP-1(7-36), liraglutide or 
GLP-1(9-36) (0.1 pM – 100 nM) to vessels contracted with phenylephrine (5 µM – 10 µM). 
To address the potential development of tachyphylaxis a single physiological concentration 
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of GLP-1(7-36) (1 nM) was added in a series of experiments. To investigate whether GLP-1 
was degraded, preparations were incubated with a dipeptidyl peptidase (DPP-4) inhibitor, 
linagliptin (10
-6
 M) before adding GLP-1. All experiments were compared to a 
phenylephrine-contracted parallel running time control vessel.  
   To consider whether the vaso-regulatory effect of GLP-1 is endothelium-dependent, we 
studied if incubation with therapeutic concentrations (10 nM) of GLP-1(7-36), liraglutide and 
GLP-1(9-36) for 20 min. before adding increasing cumulative concentrations of acetylcholine 
(0,1 nM – 10 µM), affected the acetylcholine induced relaxation in rat mesenteric arteries 
contracted with phenylephrine (10 µM). The experiments were performed at a low glucose 
concentration of 5.5 mM and at a very high glucose concentration as a model of 
hyperglycemia. In the hyperglycemia condition the vessels were incubated for at least two 
hours with 40 mM of glucose before running the protocol, as described by Salheen et al. 
(2015). The very high concentration of glucose was based on findings in previous studies, 
demonstrating that incubation with a similar high glucose concentration (44 mM) for a short 
time (4-6 hours) impaired endothelium-dependent relaxation in isolated vessels (Tesfamariam 
et al., 1991;Qian et al., 2006). The responses were examined during co-incubation with the 
GLP-1R antagonist exendin-(9-39) (100 nM). Similar experiments were performed in human 
subcutaneous arteries. Concentration-response curves for another endothelium-dependent 
relaxant, bradykinin (0.1 pM – 100 nM) was obtained in human arteries contracted with 
phenylephrine (5 µM) and preincubated with therapeutic concentrations (10 nM) of GLP-1(7-
36) and liraglutide. Furthermore, human arteries were incubated with a combination of GLP-
1(7-36) and exendin-(9-39) (100 nM) to examine whether the effect of GLP-1 is mediated 
through GLP-1 receptors. In all the experiments, equivalent solvent concentrations were 
added to a parallel running time control (vehicle). 
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   To investigate the role of superoxide in the inhibition of acetylcholine relaxations in high 
glucose, mesenteric arteries exposed to 40 mM for 2h of glucose were incubated with vehicle 
or the superoxide dismutase scavenger, tempol (10
-4
 M), and a concentration-response curve 
was constructed for acetylcholine. To clarify whether the GLP-1-receptor independent effect 
of GLP-1 on acetylcholine relaxation in high glucose is due to an antioxidant effect of GLP-
1, rat mesenteric arteries were incubated with indomethacin (10
-6
 M) and the superoxide 
generator pyrogallol (30 µM) for 30 min, phenylephrine was added, and the preparations 
were incubated with either vehicle, GLP-1 (10
-8
 M), liraglutide (10
-8
 M), tempol (10
-4
 M), or 
linagliptin (10
-6
 M). Finally, concentration-response curves were constructed for 
acetylcholine.  
Detection of vascular O2
−
 
The vascular O2
−
 was detected using the oxidative fluorescent dye dihydroethidium (Cat# 
D1137, Invitrogen, Thermo Fisher Scientific, Denmark) (Symons et al., 2006;Christensen et 
al., 2007).  Freshly dissected mesenteric arteries were placed in PSS in Ependorf vials at 37 
O
C. They were kept in normoglycemic conditions (5.5 mM glucose) or in high glucose (40 
mM) for 2½h, and those with high glucose were during the last 30 min incubated with 
vehicle, polyethylene glycol superoxide dismutase (PEG-SOD, 900 U ml
−1
), GLP-1 (10
-8
 M), 
liraglutide (10
-8
 M), or linagliptin (10
-6 
M). All segments were incubated with 
dihydroethidium (4 μmol/l) or with phosphate-buffered saline (PBS, vehicle/time control) at 
37°C in light-protected vials, rinsed once with 400 μl to PBS to remove un-oxidized 
dihydroethidium, and mounted on slides with the mounting medium Vectashield (Vector 
Laboratories, Inc. Burlingame, California). O2
-
 production was estimated using fluorescence 
microscopy (Leica, Mannheim, Germany) with an ethidium bromide excitation, 488 nm; 
Ethidium bromide emission, 580- to 630-nm band-pass filter. Fluorescence measurements 
were performed, and the vascular area measured calculated on basis of white-light pictures. 
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Identical settings were used for all vascular segments and pictures. Relative fluorescence 
intensity (RFI) was measured using the image analysis software (Fiji, RRID:SCR_002285) 
(Schindelin et al., 2012). The data are reported as PEG-SOD sensitive fluorescence. 
 
Electrical field stimulation 
Electrical field stimulation (EFS) was performed as previously described (Simonsen et al., 
2008). Platinum electrodes (2 x 2 mm) secured in plastic mounting heads were placed on 
either side of the vessel approximately 1 mm from the vessel wall. The electrodes were 
connected to an electrical stimulator with a constant current output (CS200, Danish 
Myotechnology, Aarhus, Denmark). EFS (16 Hz, 0.3 ms pulses, 10 s trains, 40 mA) was 
applied every 5 min. Increasing cumulative concentrations of GLP-1(7-36) and liraglutide 
(0,1 nM – 300 nM) were added 3 min before each stimulation. The contractile responses were 
expressed relative to an average of two initial control stimulations and compared to a parallel 
running time control. To obtain reproducible contractions, propranolol (1 µM), a β-
adrenoceptor blocker, and cocaine (1 µM), an inhibitor of neuronal noradrenalin reuptake, 
were added. The vessels were also stimulated in the presence of tetrodotoxin, a blocker of the 
voltage-gated sodium channels in nerve cell membranes. 
Data calculations and statistical analysis 
The data and statistical analysis comply with the recommendations on experimental design 
and analysis in pharmacology (Curtis et al., 2015). In view of previous experience, each 
group had to contain preparations from minimum 5-6 different subjects. Relaxation and 
contractile responses in the arteries were measured as the force ΔF (mN) developed by the 
artery, and illustrated the changes in active wall tension. Relaxation in contracted arteries was 
presented as percentage of the contraction level just before adding the relaxing agents. 
Differences in concentration-response relationships between treatments were analyzed using 
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two-way analysis of variance (ANOVA) followed by Bonferroni correction. The fluorescence 
results for vascular superoxide were compared using one-way ANOVA followed by Turkey 
multiple comparisons test. Comparison of -logEC50 values was analyzed with a t test. Results 
were considered statistically significant at p<0.05. GraphPad Prism 7 (GraphPad Prism, 
RRID:SCR_002798, Inc., San Diego, CA) was used for the statistical analysis. 
Reagents 
Acetylcholine, bradykinin, linagliptin, noradrenalin hydrochloride, phenylephrine, 
propranolol, cocaine, tempol and Glucagon-Like Peptide 1 amide Fragment 7-36 (human) 
were all purchased from Sigma-Aldrich (St Louis, MO, USA). GLP-1(7-36) amide (human, 
rat), GLP-1(9-36) amide, Exendin-3(9-39) amide, were from Tocris bioscience (Bristol, UK). 
Tetrodotoxin from BioNordika (Herlev, DK). All chemicals were dissolved in distilled water 
except for Glucagon-Like Peptide 1(7-36) human (1 % acetic acid). Victoza injection liquid 
(liraglutide) from Novo Nordisk (Copenhagen, DK) was diluted in bubbled PSS without Ca
++
 
at 37 °C. 
Nomenclature of Targets and Ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017).  
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Results 
Direct effect of GLP-1R agonists on smooth muscle cell relaxation 
In straight rat and human resistance arteries contracted with phenylephrine, native GLP-1 
failed to cause relaxation. When adding a single physiological concentration of GLP-1 (1 
nM) to the contracted vessels, the observed response was similar to the loss of tone in the 
parallel running time control (Figure 1A-B, supplementary Figure S1). Concentration-
response curves in both rat mesenteric arteries and human subcutaneous arteries showed no 
or only a very modest effect, as the observed GLP-1 mediated relaxation was close to 0% 
(Figure 1C-D). Incubation with a DPP-4 inhibitor, linagliptin (10
-6
 M) did not cause 
relaxation or increase the response to GLP-1 (Figure S1).  
   Likewise, no vasorelaxant effect was found for native GLP-1 or GLP-1(9-36) in branched 
mesenteric arteries (Figure 2A-B). Whereas liraglutide induced significant relaxation 
compared with vehicle, to approximately 40 % of maximal relaxation as demonstrated on the 
concentration-response curve in branched mesenteric arteries (Figure 2C). This effect was 
antagonized by adding of the GLP-1R antagonist exendin(9-39) (Figure 2D).  
Effect of GLP-1R agonists on the EFS evoked contractions 
EFS was performed to examine the potential influence of GLP-1 on the sympathetic nerves in 
the vascular wall. Representative traces from the EFS experiments illustrate the lack of 
inhibitory effect of GLP-1 and liraglutide on the EFS responses (Figure 3A, Figure S2), 
indicating that GLP-1 and liraglutide have no effect on the neurotransmitter-release from the 
nerves in the vascular wall. GLP-1 and liraglutide did not have any significant effect on either 
the amplitude of the contractions or the area under the contraction curve (AUC, Figure 3B-
C). Tetrodotoxin, a blocker of the voltage-gated sodium channels in nerve cell membranes, 
 
 
This article is protected by copyright. All rights reserved. 
inhibited the EFS evoked contractions. This ensured that the contractions examined here were 
due to stimulation of the nerves and not the smooth muscle cells. 
Effect of GLP-1 and liraglutide on endothelium-dependent relaxation in human subcutaneous 
arteries 
In human subcutaneous vessels from patients with peripheral arterial disease (Table 1), GLP-
1 (10
-8
 M) leftward shifted concentration relaxation curves for the endothelium-dependent 
vasodilator, bradykinin (Figure 4A). Incubation with liraglutide (10
-8
 M) failed to change the 
concentration-response curves for bradykinin in human subcutaneous arteries (Figure 
4B).Vessels were obtained from both patients diagnosed without (non-diabetics) (n=6) and 
diabetic patients (n=4). GLP-1 also leftward shifted the concentration-response curves for 
bradykinin in subcutaneous vessels from non-diabetic patients (n=6), while the effect was not 
apparent in subcutaneous arteries from patients with diabetes (n=4; Supplementary Figure 
S3). In a pooled sample of arteries from patients with and without diabetes, GLP-1 still 
leftward shifted the concentration-response curves for bradykinin in the presence of the GLP-
1R antagonist exendin(9-39) (n=5, Figure 4C).  
 Effect of GLP-1 and liraglutide on endothelium-dependent relaxation in rat mesenteric small  
arteries  
At a normoglycemic condition of 5.5 mM glucose, GLP-1 did not change the relaxation to 
acetylcholine in rat mesenteric arteries (Figure S4). In the first set of experiments with the 
model of hyperglycemia, incubation of rat mesenteric vessels with 40 mM of glucose 
significantly impaired the relaxant response to acetylcholine (Figure 5A). Based on these 
findings and to ensure, that only vessels that had actually been affected by the hyperglycemic 
condition were included in the GLP-1 study, experiments with a 40 mM glucose control 
vessel that relaxed more than 40 % at 30 nM acetylcholine was excluded (n = 6). GLP-1 
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significantly improved the relaxation to increasing concentrations of acetylcholine at a high 
glucose concentration (Figure 5B). The response to acetylcholine at high glucose in the 
presence of GLP-1 was similar to the response to acetylcholine at a low glucose 
concentration. Exendin(9-39) did not block this effect (Figure 5C). The GLP-1 potentiation of 
acetylcholine-induced relaxation was examined at GLP-1 concentrations of 0.1-10 nM, 
though only 10 nM GLP-1 significantly improved acetylcholine potency (Figure S4). The 
GLP-1 analogue, liraglutide, and the metabolite of GLP-1, GLP-1(9-36) failed to change 
acetylcholine-induced relaxations (Figure 5D and 5E). Incubation with the superoxide 
scavenger, tempol (10
-4
 M) leftward shifted concentration-response curves for acetylcholine 
in mesenteric arteries exposed to high glucose (Figure 5F). 
Effect of GLP-1 and liraglutide on vascular superoxide levels 
To investigate the role of superoxide in the effects of GLP-1, rat mesenteric arteries were 
exposed to the superoxide generator pyrogallol in the absence and the presence of GLP-1 and 
liraglutide. In the presence of pyrogallol, concentration-response curves for acetylcholine 
were leftward shifted after incubation with GLP-1 (Figure 6A), while the presence of 
liraglutide failed to change the curves for acetylcholine in arteries exposed to pyrogallol 
(Figure 6B). 
To directly measure vascular superoxide levels, the preparations were stained with DHE 
(Figure 7A-F).  The changes in fluorescence was expressed relative to the effect of the 
superoxide scavenger, PEG-SOD (Figure 7G). Incubation with high glucose (40 mM) 
markedly increased the vascular superoxide levels compared to vessels kept at 5 mM glucose. 
GLP-1 decreased the superoxide levels in vascular preparations exposed to high glucose, 
while the effect was less pronounced for liraglutide and linagliptin (Figure 7G). 
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Discussion 
The present study demonstrates that liraglutide induces vasorelaxation in branched rat 
mesenteric arteries, whereas no direct vasodilating effect and no effect on the sympathetic 
nerves in the vascular wall of native GLP-1, GLP-1(9-36) or liraglutide was found in 
resistance arteries without branches. In contrast to liraglutide, GLP-1 leftward shifted 
concentration relaxation curves for bradykinin in subcutaneous arteries from patients with 
peripheral arterial disesase, an effect insensitive to exendin(9-39). This study also suggests 
that, at a high glucose concentration, native GLP-1, by a GLP-1 receptor independent 
mechanism, may potentiate acetylcholine relaxation in small rat mesenteric arteries by 
decreasing vascular superoxide levels.  
 
The direct GLP-1 effect 
Previous studies have suggested a direct vasodilating effect of GLP-1 in isolated mesenteric 
arteries from rodents and of GLP-1R agonists in human subcutaneous arteries, as an 
explanation of the blood pressure lowering effect observed in patients treated with GLP-1R 
agonists (Ban et al., 2008;Bayram et al., 2014;Koska et al., 2015). These studies show an 
effect at GLP-1R of agonist concentrations varying from 3 pM to 3 nM. We did not find any 
direct vasodilating effect in human or rat resistance arteries without branches at similar GLP-
1 concentrations. In our experiments, GLP-1 failed to cause a relaxing response that was any 
different from the changes in artery tone in our time controls. Neither did we find any 
vasoconstricting effect of GLP-1 in mesenteric arteries as has been suggested in a previous in 
vivo study in rats (Gardiner et al., 2006). None of the studies that found a direct vasodilating 
effect of GLP-1, describe or show a time control response. Therefore, it is unclear if they 
have actually considered the changes in artery tone due to time, as an explanation of the 
observed GLP-1 induced vasodilatation.  
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   Contrary to the findings in vessels without branches, we did observe a direct vasorelaxant 
effect of liraglutide in branched rat mesenteric arteries that was inhibited by the GLP-1R 
antagonist, exendin(9-39). This finding suggests a GLP-1R-dependent and consequently 
exendin(9-39)-sensitive mechanism, consistent with the fact that liraglutide is a selective 
GLP-1R agonist. A more pronounced expression of GLP-1Rs at branching points in the 
vascular bed may explain this effect. GLP-1Rs have been found to be expressed in small 
arteries of the intestine, co-localized with smooth muscle α-actin (Richards et al., 2014), 
supporting the findings of a direct effect of liraglutide in mesenteric branched resistance 
arteries. Whether the GLP-1R expression is concentrated around branching points, remains to 
be examined in future studies. Both native GLP-1(7-36) and the metabolite GLP-1(9-36) did 
not evoke a similar response in branched rat mesenteric arteries. The concentrations of GLP-1 
and analogues thereof used in these studies (single adding: 1nM, concentration-response: 0.1 
pM - 100 nM) are comparable to plasma concentrations measured after infusion of 
therapeutic doses of GLP-1 in patients (Toft-Nielsen et al., 1999;Edwards et al., 1998), 
ensuring translational results. We therefore suggest that liraglutide induces vasorelaxation in 
branched mesenteric arteries, whereas GLP-1 and analogues has no direct vasodilating effect 
in isolated rat and human small resistance arteries without branches. 
GLP-1 effects on the vascular nerves 
GLP-1R agonists have been suggested to increase heart rate by activation of the sympathetic 
nervous system (Smits et al., 2016), and therefore, GLP-1R agonists may also regulate 
vascular tone by interaction with the nerve endings in the vascular wall similar to suggested 
effects of other gut-derived peptides (Gradin et al., 2006). This has to our knowledge, not 
been examined before. EFS is a method that enable us to activate vascular sympathetic nerve 
endings in a single isolated vessel. In our experiments, GLP-1 and liraglutide did not reduce 
the vascular contractions due to EFS and evoked by neurotransmitter release from vascular 
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sympathetic nerves in rat mesenteric arteries. Neither did they increase the responses, 
suggesting that GLP-1 and liraglutide have no effects on the vascular sympathetic nervous 
activity in rat mesenteric arteries.  
GLP-1 effect on endothelium-dependent relaxation  
A possible GLP-1 effect on endothelium-dependent relaxation at normoglycemic conditions 
was examined in both rat mesenteric and subcutaneous arteries from patients with arterial 
disease. Previous studies in patients have shown apparently conflicting results about a 
possible GLP-1 effect on vascular endothelial function. In contrast to healthy subjects, 
infusion of GLP-1 increased forearm blood flow in patients with T2D (Nystrom et al., 2004), 
and the GLP-1R agonist exenatide potentiated acetylcholine vasodilatation in adipose tissue 
arterioles (Koska et al., 2010). Others found no effect of the GLP-1R agonist liraglutide on 
endothelium-dependent vasodilatation in T2D patients (Nandy et al., 2014). As the human 
arteries used in this study were obtained from patients with arterial disease, they may have 
some degree of endothelial dysfunction. In contrast to liraglutide, GLP-1 induced a small 
leftward shift of the concentration-response curves for bradykinin in the human subcutaneous 
arteries. Previous studies have shown that exendin-4 potentiates acetylcholine vasodilatation 
in human adipose arterioles by a GLP-1 receptor-dependent mechanism (Koska et al., 2010). 
However, in the present study the effect of GLP-1 on bradykinin relaxation persisted in the 
presence of exendin(9-39) suggesting the effect is GLP-1R independent. Taken together our 
findings suggest that different mechanism are involved in the effect of, respectively, GLP-1 
and GLP-1 analogues on endothelial function in human arteries.  
   As GLP-1 did not seem to have any effects at normoglycemic conditions in rat mesenteric 
arteries, it was interesting to examine if a hyperglycemic condition comparable to the state of 
hyperglycemia in diabetic patients is required for GLP-1 to mediate its actions. Previous 
studies found that the GLP-1R agonist exendin-4 improved endothelium-dependent 
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relaxation in vessel exposed to high glucose (Salheen et al., 2015;Koska et al., 2015). We 
found that exposure of rat mesenteric arteries to high glucose impaired relaxation to 
acetylcholine, and that native GLP-1 almost reversed this high glucose induced damage. As 
acetylcholine relaxation is dependent on endothelial function our results suggest that GLP-1 
improves endothelial function in vessels that have been exposed to hyperglycemia, consistent 
with the findings by Salheen et al. (2015) and Koska et al. (2015). A GLP-1 concentration of 
10 nM was required to significantly increase the potency of acetylcholine (Figure S4), a 
concentration similar to the plasma concentrations measured after subcutaneous injection of 
therapeutic concentrations of liraglutide (Danne et al., 2017;Damholt et al., 2006). 
Liraglutide or the cleaved metabolite of GLP-1, GLP-1(9-36), did not reproduce the effect of 
GLP-1. This can be due to differences in chemical structure of GLP-1 and liraglutide (Lund 
et al., 2014). Nevertheless, we found an effect of GLP-1 on hyperglycemia-induced 
impairment of endothelium-dependent relaxation, but as we were not able to show a similar 
effect of liraglutide, it is uncertain if this is the major mechanism resulting in the lowering of 
blood pressure in diabetic patients treated with GLP-1 analogues. Furthermore, it is 
noteworthy that GLP-1 plasma levels have been found to be associated with blood pressure in 
normoglycemic young healthy adults as well (Krisai et al., 2015), demonstrating that there 
may be other GLP-1 effects of importance that impacts blood pressure. 
   Exendin(9-39) did not attenuate the effect of GLP-1 suggesting that the effect is 
independent of the GLP-1R. This assumption is conflicting with the results by Salheen et al. 
(2015), indicating that further studies are needed to confirm the possible GLP-1R 
dependence- or independency. However, previous investigations suggested that exendin-4 
and the DPP-4 inhibitor, linagliptin potentiate acetylcholine relaxations in rat mesenteric 
arteries exposed to high glucose by a mechanism decreasing vascular superoxide levels 
(Salheen et al., 2015). It has also been shown that native GLP-1 decreases monocyte-derived 
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oxidative stress (Steven et al., 2016). In the present study, a superoxide dismutase mimetic, 
tempol, leftward shifted concentration-response curves for acetylcholine in arteries exposed 
to high glucose suggesting vascular superoxide levels play a role in high glucose impairment 
of acetylcholine relaxation. Moreover, we found that GLP-1 prevented impairment of 
acetylcholine relaxation by the superoxide generator pyrogallol, while this was not the case 
for liraglutide. Finally, measurements of vascular superoxide levels by use of dihydroethium 
revealed that GLP-1 markedly decreased the levels. Our results suggest that one vascular 
action of therapeutic concentrations of native GLP-1, but not of liraglutide or GLP-1(9-36), is 
that it improves endothelium-dependent relaxation at a high glucose concentration, possibly 
by a GLP-1R-independent pathway involving inhibition of vascular superoxide levels. 
Conclusions  
In summary, in normoglycemic conditions a GLP-1R-dependent mechanism is involved in 
liraglutide relaxation in branched arteries, while GLP-1 and analogues at therapeutic 
concentrations have no direct vasodilating effect on the smooth muscle cells in arterial 
segments without branches and no pre-junctional effect on the neurotransmitter release from 
the sympathetic vascular nerves. We found that inhibition of vascular superoxide levels 
contributes to the GLP-1 receptor-independent potentiation of endothelium-dependent 
vasodilatation in hyperglycemic conditions. The latter mechanism may play a role in GLP-1 
induced leftward shift of concentration relaxation curves for bradykinin in subcutaneous 
arteries from patients with peripheral arterial disease. These studies suggest that different 
mechanisms are involved in GLP-1 and liraglutide induced vasodilatation in small arteries, 
and may contribute to the blood pressure lowering effect of GLP-1 analogues previously 
observed in treatment of type 2 diabetic patients. 
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Figure 1. Lack of vasodilatation to native GLP-1 in rat mesenteric and human 
subcutaneous arteries without branches. (A, B) Representative original traces from the 
myograph experiments in rat mesenteric arterial segments. Both vessels relax to a sufficient 
level when adding acetylcholine. (A) Time control contracted with phenylephrine. (B) Vessel 
contracted with phenylephrine and exposed to a single physiological concentration of GLP-1. 
Concentration-response curves for GLP-1 in (C) rat mesenteric arteries (n=7) and (D) human 
subcutaneous arteries (n=9). The results are means ± s.e.mean.  
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Figure 2. Vasodilatation induced by liraglutide in rat mesenteric arteries with branches. 
Concentration-response curves for (A) native GLP-1 (n=6) and vehicle (n=6), (B) GLP-1(9-
36) (n=6) and vehicle (n=6), (C) liraglutide (n=6) and vehicle (n=6), (D) liraglutide (n=6) and 
liraglutide plus exendin(9-39) (n= 6). The results are means ± s.e.mean. 2-way ANOVA, 
*P<0.05.  
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Figure 3. Lack of effect of native GLP-1 and liraglutide on neurogenic contractions in 
rat mesenteric arteries. (A) Representative original traces showing contractions induced by 
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electrical field stimulation in the absence and the presence of increasing concentrations (M) 
of native GLP-1 and liraglutide. Squares mark stimulation intervals (10 s). The traces are 
each representative of 5-6 different experiments. (B) Enlargement of the responses showing 
area under the response curve (AUC) at one control stimulation and after adding native GLP-
1 (10
-8
 M), (C) Average AUC for the contractions in experiments where vehicle (n=6), GLP-
1 (n=6), or liraglutide (n=5) was added. AUC of the contractions are presented as percentage 
of an initial control stimulation. Data are presented as means ± s.e.mean. Unpaired t-test 
showed no significant difference between treatments. 
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Figure 4: Bradykinin induced relaxation in human subcutaneous arteries. (A) Average 
concentration-response curves for bradykinin in the absence (n=10) and in the presence of 
GLP-1 (10
-8
 M, n=10). (B) Concentration-response curves for bradykinin in the absence 
(n=10) and in the presence of liraglutide (10
-8
 M, n=10). (C) Average concentration-response 
curves for bradykinin in the absence and in the presence of GLP-1 (10
-8
 M), and GLP-1 plus 
the GLP-1 receptor antagonist, exendin(9-39) (n=5). The results are means ± s.e.mean. 
*P<0.05, 2-way ANOVA followed by Bonferroni post-test. 
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Figure 5: GLP-1 potentiates acetylcholine-induced relaxation in rat mesenteric arteries 
kept in high glucose. Concentration-response curves for acetylcholine (ACh) in rat 
meseneric arteries without branches kept (A) at 5.5 mM (n=13) and 40 mM (n=15) glucose, 
(B) at 40 mM glucose in the absence (n=11) and in the presence of GLP-1 (10
-8
 M, n=12), 
(C) at 40 mM glucose in the presence of GLP-1 (10
-8
 M) without (n=11) and with (n=4) 
exendin-(9-39), (D) at 40 mM glucose in the absence (n=9) and the presence of liraglutide 
(10
-8
 M, n=10), (E) at 40 mM glucose in the absence (n=10) and the presence of GLP-1 (9-
36) (10
-8
 M, n=5). (F) at 40 mM glucose in the absence (n=10) and the presence of the 
superoxide dismutase mimetic, tempol (10
-4
 M, n=10), and at 5.5 mM glucose (n=10). 
Results are means ± s.e.mean. *P<0.05, 2-way ANOVA followed by Bonferroni post-test. 
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Figure 6. GLP-1 potentiates acetylcholine-induced relaxation in rat mesenteric arteries 
exposed to the superoxide generator, pyrogallol. Concentration-response curves for 
acetylcholine (ACh) in rat mesenteric arteries without branches exposed to the superoxide 
generator, pyrogallol (3x10
-5
 M) (A) in the absence (n=10) and the presence of GLP-1 (10
-8
 
M, n=10) or (B) in the absence (n=10) and the presence of liraglutide (10
-8
 M, n=10). The 
experiments were performed in the presence of indomethacin (10
-6
 M). Results are means ± 
s.e.mean. *P<0.05, 2-way ANOVA followed by Bonferroni post-test. 
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Figure 7. Dihydroethidium staining of rat mesenteric arteries is increased by high 
glucose and decreased by GLP-1. Representative fluorescent photomicrographs of 
mesenteric arteries incubated in (A) normoglycemic conditions (5.5 mM glucose), and (B) 40 
mM glucose, (C) 40 mM glucose and PEG-SOD (500 U L
-1
), (D) 40 mM glucose and GLP-1 
(10
-8
 M), (E) 40 mM glucose and liraglutide (10
-8
 M), or (F) 40 mM glucose and linagliptin 
(10
-6
 M). White bars correspond to 50 µm. (G) Average results for dihydroethidium staining 
obtained in arteries from 9 animals. Columns are means (n=9) ± s.e.mean. *P<0.05 versus 5 
mM glucose, # P<0.05 versus 40 mM glucose exposed vessels using one-way ANOVA 
followed by Tukey's multiple comparisons test. 
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Data are means ± SD or n (%). 
Table 1 – Clinical characteristics of included patients 
Variables Study population (N = 23) 
Age (years) 72,5 ± (8.8) 
Male gender  14 (61%) 
Blood glucose (mM) 7.1 ± (3.3) 
Systolic Blood pressure (mmHg) 145.7 ± (16) 
Diastolic blood pressure (mmHg) 77.3 ± (13.6) 
Cholesterol (mM) 4.3 ± (1.1) 
Smokers  12 (52%) 
Previous smokers 23 (100%) 
DM II 9 (39%) 
Peripheral artery disease (PAD)  15 (65%) 
Hypertension 13 (57%) 
Lipid-lowering therapy 21 (91%) 
DPP-4 inhibitor treatment  0 (0%) 
 
 
 
 
